Matt O'Brien
Stock Analyst at Piper Sandler
(2.21)
# 2,783
Out of 5,124 analysts
195
Total ratings
42.68%
Success rate
-4.82%
Average return
Main Sectors:
Stocks Rated by Matt O'Brien
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GMED Globus Medical | Reiterates: Overweight | $90 → $115 | $87.81 | +30.96% | 13 | Jan 8, 2026 | |
| KMTS Kestra Medical Technologies | Maintains: Overweight | $27 → $30 | $25.51 | +17.60% | 2 | Dec 12, 2025 | |
| TELA TELA Bio | Reiterates: Neutral | $2 → $1.25 | $0.82 | +53.37% | 7 | Nov 14, 2025 | |
| SI Shoulder Innovations | Reiterates: Overweight | $18 | $12.74 | +41.29% | 2 | Nov 12, 2025 | |
| CNMD CONMED | Maintains: Overweight | $68 → $55 | $41.52 | +32.47% | 14 | Nov 6, 2025 | |
| PRCT PROCEPT BioRobotics | Reiterates: Overweight | $55 → $50 | $28.74 | +73.97% | 5 | Nov 5, 2025 | |
| DXCM DexCom | Maintains: Overweight | $100 → $75 | $69.97 | +7.19% | 13 | Oct 31, 2025 | |
| ATEC Alphatec Holdings | Reiterates: Overweight | $20 → $25 | $13.82 | +80.90% | 4 | Oct 31, 2025 | |
| TMDX TransMedics Group | Maintains: Overweight | $145 → $140 | $135.06 | +3.66% | 13 | Oct 30, 2025 | |
| BBNX Beta Bionics | Reiterates: Overweight | $26 → $32 | $13.08 | +144.65% | 2 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $155 → $82 | $86.45 | -5.15% | 3 | Oct 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $22 | $16.65 | +32.13% | 3 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $11.67 | +54.24% | 1 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $30 → $14 | $19.17 | -26.97% | 9 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $12 | $6.55 | +83.21% | 9 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $180 → $165 | $112.52 | +46.64% | 10 | Apr 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5.5 → $3.5 | $5.87 | -40.37% | 7 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $255 → $140 | $108.42 | +29.13% | 5 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $285 → $310 | $241.93 | +28.14% | 8 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $250 → $330 | $341.02 | -3.23% | 13 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $50 | $37.11 | +34.73% | 3 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $40 → $16 | $17.58 | -8.99% | 7 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $95 → $115 | $76.27 | +50.78% | 3 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $9 → $12 | $3.90 | +207.69% | 7 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $380 → $420 | $358.29 | +17.22% | 12 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $85 → $90 | $102.90 | -12.54% | 9 | Aug 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $25 | $15.60 | +60.31% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3.5 → $3 | $0.94 | +219.73% | 2 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $4.5 | $3.88 | +15.98% | 2 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $89.91 | - | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $15 | $3.94 | +280.71% | 1 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $93 → $109 | $82.10 | +32.46% | 1 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $100 → $80 | $21.73 | +268.15% | 1 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $12 | $4.92 | +143.90% | 1 | Jun 24, 2020 |
Globus Medical
Jan 8, 2026
Reiterates: Overweight
Price Target: $90 → $115
Current: $87.81
Upside: +30.96%
Kestra Medical Technologies
Dec 12, 2025
Maintains: Overweight
Price Target: $27 → $30
Current: $25.51
Upside: +17.60%
TELA Bio
Nov 14, 2025
Reiterates: Neutral
Price Target: $2 → $1.25
Current: $0.82
Upside: +53.37%
Shoulder Innovations
Nov 12, 2025
Reiterates: Overweight
Price Target: $18
Current: $12.74
Upside: +41.29%
CONMED
Nov 6, 2025
Maintains: Overweight
Price Target: $68 → $55
Current: $41.52
Upside: +32.47%
PROCEPT BioRobotics
Nov 5, 2025
Reiterates: Overweight
Price Target: $55 → $50
Current: $28.74
Upside: +73.97%
DexCom
Oct 31, 2025
Maintains: Overweight
Price Target: $100 → $75
Current: $69.97
Upside: +7.19%
Alphatec Holdings
Oct 31, 2025
Reiterates: Overweight
Price Target: $20 → $25
Current: $13.82
Upside: +80.90%
TransMedics Group
Oct 30, 2025
Maintains: Overweight
Price Target: $145 → $140
Current: $135.06
Upside: +3.66%
Beta Bionics
Oct 29, 2025
Reiterates: Overweight
Price Target: $26 → $32
Current: $13.08
Upside: +144.65%
Oct 24, 2025
Maintains: Overweight
Price Target: $155 → $82
Current: $86.45
Upside: -5.15%
Oct 10, 2025
Maintains: Overweight
Price Target: $30 → $22
Current: $16.65
Upside: +32.13%
Aug 18, 2025
Initiates: Overweight
Price Target: $18
Current: $11.67
Upside: +54.24%
Aug 7, 2025
Downgrades: Neutral
Price Target: $30 → $14
Current: $19.17
Upside: -26.97%
May 9, 2025
Maintains: Overweight
Price Target: $20 → $12
Current: $6.55
Upside: +83.21%
Apr 15, 2025
Maintains: Overweight
Price Target: $180 → $165
Current: $112.52
Upside: +46.64%
Mar 6, 2025
Maintains: Neutral
Price Target: $5.5 → $3.5
Current: $5.87
Upside: -40.37%
Feb 28, 2025
Downgrades: Neutral
Price Target: $255 → $140
Current: $108.42
Upside: +29.13%
Feb 21, 2025
Maintains: Overweight
Price Target: $285 → $310
Current: $241.93
Upside: +28.14%
Feb 19, 2025
Reiterates: Overweight
Price Target: $250 → $330
Current: $341.02
Upside: -3.23%
Feb 13, 2025
Maintains: Overweight
Price Target: $40 → $50
Current: $37.11
Upside: +34.73%
Feb 12, 2025
Maintains: Neutral
Price Target: $40 → $16
Current: $17.58
Upside: -8.99%
Feb 3, 2025
Maintains: Overweight
Price Target: $95 → $115
Current: $76.27
Upside: +50.78%
Nov 8, 2024
Reiterates: Neutral
Price Target: $9 → $12
Current: $3.90
Upside: +207.69%
Oct 30, 2024
Reiterates: Overweight
Price Target: $380 → $420
Current: $358.29
Upside: +17.22%
Aug 21, 2024
Maintains: Neutral
Price Target: $85 → $90
Current: $102.90
Upside: -12.54%
Mar 28, 2024
Initiates: Overweight
Price Target: $25
Current: $15.60
Upside: +60.31%
Nov 10, 2023
Maintains: Neutral
Price Target: $3.5 → $3
Current: $0.94
Upside: +219.73%
Aug 11, 2023
Maintains: Overweight
Price Target: $4 → $4.5
Current: $3.88
Upside: +15.98%
Mar 10, 2023
Upgrades: Overweight
Price Target: n/a
Current: $89.91
Upside: -
Feb 24, 2023
Initiates: Overweight
Price Target: $15
Current: $3.94
Upside: +280.71%
Feb 11, 2021
Maintains: Overweight
Price Target: $93 → $109
Current: $82.10
Upside: +32.46%
Jan 29, 2021
Downgrades: Neutral
Price Target: $100 → $80
Current: $21.73
Upside: +268.15%
Jun 24, 2020
Initiates: Overweight
Price Target: $12
Current: $4.92
Upside: +143.90%